

BioMed X Innovation Center

Fact Sheet

The BioMed X Innovation Center is an exciting new collaboration model at the interface between academia and industry. At our center, distinguished early career scientists recruited from all over the world are working jointly on novel pre-clinical research projects in the fields of biomedicine, molecular biology, cell biology, and diagnostics. These interdisciplinary project teams are conducting groundbreaking biomedical research in an open innovation lab facility on the campus of the University of Heidelberg, Germany. They are working under the guidance of experienced mentors from academia and industry while expanding their scientific network and receiving entrepreneurship and leadership training. Each team is typically supported by a corporate pharma partner of BioMed X. After a fully funded project term, successful projects are internalized into the development pipeline of the respective pharma partner.

BioMed X's facilities are based in an open innovation lab facility at the Technology Park on the campus of the University of Heidelberg, Germany and are embedded within the Life Science Campus Neuenheimer Feld, surrounded by renowned research institutes such as University of Heidelberg, German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT), European Molecular Biology Laboratory (EMBL), Center for Molecular Biology (ZMBH), Heidelberg University Hospital with 44 specialized clinical departments, and approximately 100 large and small life science companies.

HQ and Facilities:	Im Neuenheimer Feld 515 and 583 69120 Heidelberg Germany
	Phone: +49 6221 426 110 E-Mail: info@bio.mx www.bio.mx
Employees:	> 60
Diversity:	approx. 50 % male, 50 % female > 20 nationalities
Facilities:	1,800 sqm laboratory and office space
Founding Year:	2013
Sponsors:	AbbVie Boehringer Ingelheim Janssen Merck KGaA Roche
Research Projects:	8 currently active (12 total)
Research Areas:	oncology, immunology, neuroscience, respiratory, diagnostics, (bio.mx/research-teams)

New Innovation Model ([Betz & Tidona 2015: Nature Biotechnology 33, pp. 20-21](#)):

1. Definition of an ambitious R&D challenge which, if solved, would add significant value to the corporate partner's product development pipeline;
2. World-wide publication of the challenge and crowdsourcing of the best ideas and talents addressing the challenge (on average BioMed X receives 200-400 project proposals from 60-80 countries per challenge);
3. Selection and invitation of the 15 best candidates to a 5-day boot camp in Heidelberg (purpose: interdisciplinary team building, mentorship, conversion of outstanding ideas into well-designed project proposals);
4. Selection and relocation of 2-3 winning candidates for a 3-5 year fellowship at the BioMed X Innovation Center in Heidelberg (pharma / biotech partner financially supports its BioMed X research teams including overhead and management fee, all generated IP is transferred to pharma / biotech partner against payment of a pre-negotiated success fee at the end of the project term).

Value Proposition for Pharma Partners:

- Access to outstanding international academic talents who would normally not apply for a job at big pharma;
- Cost-effective global crowdsourcing of original project proposals (vs world-wide business development efforts);
- Cross-pollination of international top talents via relocation to a joint open innovation lab in Heidelberg;
- Access to academic research infrastructure and the BioRN Network in Heidelberg, one of the strongest biomedical innovation hubs in Europe (e.g. University of Heidelberg, German Cancer Research Center, National Center for Tumor Diseases, European Molecular Biology Laboratory, Center for Molecular Biology, Heidelberg University Hospital with 44 specialized clinical departments, around 100 large and small life science companies);
- Ownership of generated intellectual property (no milestone payments or royalties);
- Novel combination of crowdsourcing, open innovation and incubator approaches.